COVID-19

No items found.

Latest posts in

COVID-19

Covid-19 update: Omicron may be more dangerous for children
Covid-19 update: Omicron may be more dangerous for children

Global: The global Covid death toll has passed the grim milestone of 5.5 million, with a figure of 5,565,197 according…

Read
Merck-Ridgeback to supply courses of Covid-19 oral antiviral to UNICEF
Merck-Ridgeback to supply courses of Covid-19 oral antiviral to UNICEF

Merck will allocate the oral antiviral courses to UNICEF for supply in over 100 countries in the first half of…

Read
Moderna eyes combined Covid-19, flu booster by 2023
Moderna eyes combined Covid-19, flu booster by 2023

Moderna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.

Read
Covid-19 update: Fourth shot of vaccine can’t prevent Omicron infections
Covid-19 update: Fourth shot of vaccine can’t prevent Omicron infections

Global: The global Covid death toll has passed the grim milestone of 5.5 million, with a figure of 5,545,923 according…

Read
Health Canada grants authorisation to Pfizer’s Paxlovid for Covid-19
Health Canada grants authorisation to Pfizer’s Paxlovid for Covid-19

The authorised dosage is two tablets of nirmatrelvir and one tablet of ritonavir given orally twice daily for five days.

Read
Medlab receives grant to develop NanoCelle nasal vaccine for Covid-19
Medlab receives grant to develop NanoCelle nasal vaccine for Covid-19

The company will collaborate with the University of NSW and Macquarie University for vaccine development.

Read
Covid-19 news: Billionth Covax program vaccine delivered
Covid-19 news: Billionth Covax program vaccine delivered

Global: The global Covid-19 death toll has passed the grim milestone of 5.5 million, with a figure of 5,539,681 according…

Read
WHO recommends GSK-Vir and Lilly’s drugs for Covid-19 treatment
WHO recommends GSK-Vir and Lilly’s drugs for Covid-19 treatment

GSK-Vir’s sotrovimab was demonstrated to retain activity against Omicron variant in initial laboratory studies.

Read

Do you like our stuff? Subscribe now.

Five main reasons to sign up for our newsletter